• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria

by | Sep 24, 2024 | Publications

Leuk Lymphoma. 2024 Sep 24:1-10. doi: 10.1080/10428194.2024.2395440. Online ahead of print. ABSTRACT Patients with certain subsets of multiple myeloma continue to have poor outcomes and are in need of novel treatment approaches. Strict eligibility criteria for...

Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis

by | Sep 18, 2024 | Publications

PLoS One. 2024 Sep 6;19(9):e0308463. doi: 10.1371/journal.pone.0308463. eCollection 2024. ABSTRACT INTRODUCTION: Patients with multiple myeloma (MM) face heightened infection susceptibility, particularly severe risks from COVID-19. This study, the first systematic...

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis

by | Sep 18, 2024 | Publications

Hematology. 2024 Dec;29(1):2399430. doi: 10.1080/16078454.2024.2399430. Epub 2024 Sep 9. ABSTRACT BACKGROUND: Renal insufficiency (RI) is a key factor affecting the prognosis of multiple myeloma (MM) patients. Because the benefit of daratumumab for treating MM...

Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era

by | Sep 18, 2024 | Publications

Clin Exp Med. 2024 Sep 9;24(1):215. doi: 10.1007/s10238-024-01481-2. ABSTRACT The benefit of high-dose melphalan followed by autologous hematopoietic stem cell transplantation (HDM-ASCT) for multiple myeloma (MM) patients with renal insufficiency (RI) is debated. A...

Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review

by | Sep 18, 2024 | Publications

Heliyon. 2024 Aug 13;10(16):e36311. doi: 10.1016/j.heliyon.2024.e36311. eCollection 2024 Aug 30. ABSTRACT BACKGROUND: Even with significant advancements, treating multiple myeloma (MM) remains difficult. At present, the main treatment methods include combined...

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

by | Sep 18, 2024 | Publications

Clin Cancer Res. 2024 Sep 11. doi: 10.1158/1078-0432.CCR-24-1798. Online ahead of print. ABSTRACT PURPOSE: CAR T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events including second primary...
« Older Entries
Next Entries »

Recent Content

  • Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
  • Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
  • Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
  • FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma
  • Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT